Keeping Track: FDA Issues Three Four-Month Approvals: Ninlaro, Darzalex, And Narcan Nasal Spray
Executive Summary
The latest drug development news and highlights from our FDA Performance Tracker.
You may also be interested in...
Cost Concerns May Hinder Naloxone Co-Prescribing Ideas
US FDA estimates mandating naloxone co-prescriptions could dramatically increase spending to more than total estimated cost of opioid crisis itself; joint advisory committee to consider options to increase naloxone availability.
FDA’s Naloxone Product Approval Standards May See Changes
Advisory committees will weigh adequacy of current pharmacokinetic requirements and pediatric dosing for novel formulations of the opioid overdose reversal agent.
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.